Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
GRODMAN MARC
  2. Issuer Name and Ticker or Trading Symbol
BIO REFERENCE LABORATORIES INC [BRLI]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President, CEO
(Last)
(First)
(Middle)
481 EDWARD H. ROSS DRIVE
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2009
(Street)

ELMWOOD PARK, NJ 07407
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2009   S(1)(2)   42,603 (1) (2) D $ 22.39 1,233,834 D  
Common Stock               226,667 (3) I By wife and children

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Forward Contract (Right/Obligation to Sell) (1) (2) 12/21/2006   J     0 (1) (2)   (1)(2)   (1)(2) Common Stock (1) (2) (1) (2) 0 (1) (2) D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
GRODMAN MARC
481 EDWARD H. ROSS DRIVE
ELMWOOD PARK, NJ 07407
  X   X   President, CEO  

Signatures

 /s/ Roger Tolins - Attorney-in-Fact for Marc D. Grodman   01/22/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On October 12, 2006, Marc D. Grodman established a Rule l0b-5-1 Sales Plan with Bear Stearns & Co., Inc. ("Bear Stearns") to facilitate sales of a variable number of Dr. Grodman's shares of BRLI Common Stock (up to 200,000 shares) in variable pre-paid forward transactions ("Forward Transactions") at a minimum per share sale price as specified in the Sales Plan. In connection with the contemplated Forward Transactions, Dr. Grodman pledged 200,000 shares of his BRLI Common Stock to secure his obligation to deliver a maximum aggregate 200,000 shares of Common Stock to Bear Stearns on the final settlement dates (varying from 23 to 25 months after each sale). The Sales Plan was terminated on December 21, 2006 at which date an aggregate 175,936 shares had been sold pursuant to the Forward Transactions. (Continued - Footnote 2)
(2) As prepayment for the pledge of these shares, Bear Stearns paid Dr. Grodman approximately $3,950,000 or approximately $22.46 per share. The number of shares that Dr. Grodman will be obligated to deliver on the final settlement dates will vary based upon the market price of the Common Stock on such settlement dates. Dr. Grodman will benefit from any excess in the market prices of the Common Stock at the final settlement dates to the extent such prices exceed approximately $25.30 up to approximately $30.38 per share, by being able to deliver fewer shares. Until the final settlement dates, Dr. Grodman is deemed the beneficial owner of the pledged shares.
(3) Includes 173,467 shares owned directly by Dr. Grodman's wife and 53,200 shares owned by their children. The reporting person disclaims beneficial ownership of these 226,667 shares.
 
Remarks:
Based on the closing price for BRLI Common Stock on the NASDAQ Global Market System on November 18, 2008, the settlement date with respect to the first 66,666 shares of the aggregate 175,936 shares sold, Dr. Grodman transferred 66,666 of the pledged shares to Bear Stearns, now a division of J.P. Morgan, for which he had received a prepayment of $1,497,343.  The net effect to Dr. Grodman is that on the initial settlement date, he sold 66,666 shares at a price of $22.46 per share.

Based on the closing price for BRLI Common Stock on the NASDAQ Global Market System on December 18, 2008, the settlement date with respect to the second 66,666 shares of the aggregate 175,936 shares sold, Dr. Grodman was obliged to deliver only 63,976 of the pledged shares to Bear Stearns, now a division of J.P. Morgan, for which he had received a prepayment of $1,497,272.  The net effect to Dr. Grodman is that on the second settlement date, he sold 63,976 shares at a price of $23.40 per share.

Based on the closing price for BRLI Common Stock on the NASDAQ Global Market System on January 21, 2009, the settlement date with respect to the final 42,603 shares of the 175,936 shares sold, as of January 21, 2009, Dr. Grodman transferred 42,603 of the pledged shares to the Bear Stearns division of J.P. Morgan for which he had received a prepayment of $953,941.  The net effect to Dr. Grodman is that on the third (final) settlement date, he sold 42,603 shares at a price of $22.39 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.